- Title
- Predictors of long-term progression-free survival in patients treated with niraparib first-line maintenance therapy in the phase 3 randomised placebo-controlled PRIMA/ENGOT-OV16/GOG-3012 trial
- Creators
- Antonio González-Martín - Centro de Investigación Médica AplicadaDavid M. O'Malley - The Ohio State UniversityCristina Churruca Galaz - Medical Oncology Department, Hospital Universitario Donostia, San Sebastian, SpainChristof Vulsteke - AZ Maria MiddelaresDana M. Chase - University of California, Los AngelesAnthoula Koliadi - Uppsala University HospitalPatricia Braly - Womens Cancer Care, Covington, Louisiana, United StatesDomenica Lorusso - Università Cattolica del Sacro CuoreJohn K. Chan - Palo Alto Medical FoundationVéronique D'Hondt - Institut du Cancer de Montpellier (ICM), Val d’Aurelle, Montpellier, and GINECO, Montpellier, FranceLyndsay J. Willmott - Arizona Center for Cancer Care, Phoenix, Arizona, United StatesBradley J. Monk - Gynecologic Oncology Groupet al.
- Publication Details
- International journal of gynecological cancer, Vol.36(2), p.103081
- Publisher
- Elsevier Inc
- Identifiers
- 991006256541302656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
Predictors of long-term progression-free survival in patients treated with niraparib first-line maintenance therapy in the phase 3 randomised placebo-controlled PRIMA/ENGOT-OV16/GOG-3012 trial
International journal of gynecological cancer, Vol.36(2), p.103081
02/2026
Metrics
1 Record Views